Eli Lilly And Company ((LLY)), Rigel Pharmaceuticals ((RIGL)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
In a recent update, Eli Lilly and Company, in collaboration with Rigel Pharmaceuticals, is conducting an adaptive Phase 2a/2b study titled ‘An Adaptive Phase 2a/2b, Randomized, Double-Blind, Placebo-Controlled Study of LY3871801 in Adult Participants With Moderately-to-Severely Active Rheumatoid Arthritis.’ The study aims to assess the efficacy and safety of the drug LY3871801 in treating adults with active moderately-to-severe rheumatoid arthritis, a condition that significantly impacts quality of life.
The intervention being tested is LY3871801, an orally administered drug, compared against a placebo. The study involves multiple phases, with participants receiving different doses of LY3871801 to evaluate its effectiveness and safety profile.
This interventional study employs a randomized, parallel assignment model with double masking to ensure unbiased results. The primary purpose is treatment, focusing on evaluating the therapeutic potential of LY3871801.
The study began on May 23, 2023, and is currently recruiting participants. The last update was submitted on July 22, 2025, indicating ongoing progress. These dates are crucial as they reflect the study’s timeline and current status.
The outcome of this study could significantly influence Eli Lilly’s and Rigel Pharmaceuticals’ stock performance, as positive results might boost investor confidence and market share, especially in the competitive rheumatoid arthritis treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.